Chan Henry Lee Sells 332 Shares of BeOne Medicines (NASDAQ:ONC) Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) SVP Chan Henry Lee sold 332 shares of the firm’s stock in a transaction on Wednesday, April 8th. The stock was sold at an average price of $311.59, for a total transaction of $103,447.88. Following the transaction, the senior vice president directly owned 318,370 shares in the company, valued at $99,200,908.30. The trade was a 0.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Chan Henry Lee also recently made the following trade(s):

• On Wednesday, March 11th, Chan Henry Lee sold 341 shares of BeOne Medicines stock. The shares were sold at an average price of $300.00, for a total transaction of $102,300.00.
• On Wednesday, February 4th, Chan Henry Lee sold 1,660 shares of BeOne Medicines stock. The stock was sold at an average price of $349.52, for a total value of $580,203.20.

BeOne Medicines Stock Performance

ONC stock traded down $3.76 during trading on Friday, hitting $309.66. The company had a trading volume of 134,413 shares, compared to its average volume of 264,760. The firm has a 50-day moving average price of $316.84 and a 200-day moving average price of $324.95. The company has a quick ratio of 3.08, a current ratio of 3.41 and a debt-to-equity ratio of 0.22. The firm has a market cap of $33.98 billion, a PE ratio of 122.88 and a beta of 0.53. BeOne Medicines Ltd. – Sponsored ADR has a 1-year low of $218.31 and a 1-year high of $385.22.

BeOne Medicines (NASDAQ:ONC) last posted its quarterly earnings data on Thursday, February 26th. The company reported $0.58 earnings per share for the quarter, missing analysts’ consensus estimates of $1.60 by ($1.02). BeOne Medicines had a return on equity of 10.70% and a net margin of 5.37%.The company had revenue of $1.50 billion for the quarter, compared to analyst estimates of $1.45 billion. On average, analysts expect that BeOne Medicines Ltd. – Sponsored ADR will post -5.82 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in ONC. EFG International AG purchased a new position in BeOne Medicines in the fourth quarter valued at about $25,000. Anchor Investment Management LLC acquired a new position in BeOne Medicines during the second quarter worth $26,000. Leonteq Securities AG acquired a new position in BeOne Medicines during the fourth quarter worth $35,000. Daiwa Securities Group Inc. acquired a new position in BeOne Medicines during the second quarter worth $35,000. Finally, CWM LLC raised its holdings in BeOne Medicines by 32.8% during the fourth quarter. CWM LLC now owns 158 shares of the company’s stock worth $48,000 after purchasing an additional 39 shares during the last quarter. 48.55% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on ONC. Barclays upped their price objective on shares of BeOne Medicines from $394.00 to $405.00 and gave the stock an “overweight” rating in a research report on Friday, February 27th. Sanford C. Bernstein upgraded shares of BeOne Medicines from a “hold” rating to an “outperform” rating and set a $414.00 price target on the stock in a research note on Monday, January 12th. Wall Street Zen lowered BeOne Medicines from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 28th. Jefferies Financial Group downgraded BeOne Medicines from a “buy” rating to a “hold” rating and decreased their price target for the company from $420.00 to $290.00 in a research note on Monday, March 16th. Finally, Wolfe Research began coverage on BeOne Medicines in a research report on Friday, March 27th. They issued an “outperform” rating and a $340.00 price objective for the company. Eleven analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, BeOne Medicines currently has an average rating of “Moderate Buy” and a consensus target price of $385.08.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.